Top 5 Papers
#1
Source: Cancer Cell | Authors: Entrialgo-Cadierno R, Morali K, Feliu I, et al. | Published: April 23, 2026
Score: 11/20 — Base 9 (Cancer Cell) + 2 (novel target / new SOC potential in CCA)
About 25% of cholangiocarcinomas (CCA) harbor KRAS mutations. This translational study showed that RAS(ON) multi-selective inhibitors — which target the active GTP-bound state of mutant and wild-type RAS — produce strong responses across cell lines, patient-derived xenografts, and immunocompetent allograft CCA models. Crucially, the authors describe clinical activity of the RAS(ON) inhibitor daraxonrasib in two patients with advanced KRAS G12 CCA, with objective partial responses. RAS-GTP inhibition also potentiated standard-of-care CCA regimens, prolonging survival in xenografts. Resistance was mainly driven by re-activation of RAS signaling. These findings open a new molecularly targeted avenue for biliary tract cancer beyond FGFR2 and IDH1, and support clinical evaluation of daraxonrasib in KRAS-mutant CCA.
Post angle: Daraxonrasib breaks new ground beyond pancreas: 2 patients with KRAS G12 cholangiocarcinoma achieved objective partial responses, plus broad preclinical efficacy across CCA models. KRAS-mutant biliary cancer just got its first credible targeted lead. Watch for a CCA registrational trial. #Cholangiocarcinoma #BiliaryCancer #KRAS #PrecisionOncology #GIOnc
#2
Source: Press Release / FDA Action (Jazz Pharmaceuticals · BeOne Medicines · Zymeworks) | Authors: Jazz Pharmaceuticals | Published: April 27, 2026
Score: 11/20 — Base 8 (FDA Priority Review) + 3 (potential new 1L SOC for HER2+ GEA)
The FDA accepted the supplemental BLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ unresectable locally advanced or metastatic gastric, GEJ, and esophageal adenocarcinoma (GEA) and granted Priority Review with a PDUFA target action date of August 25, 2026. The decision rests on the global Phase 3 HERIZON-GEA-01 trial (914 patients, ~300 sites, 30+ countries): the zanidatamab + chemotherapy + tislelizumab arm achieved median OS of 26.4 months and the zanidatamab + chemotherapy arm 24.4 months, versus 19.2 months for trastuzumab + chemotherapy (control); both experimental arms also met PFS (12.4 vs 8.1 months). If approved, zanidatamab combinations would offer the first credible challenger to trastuzumab-based regimens in 1L HER2+ GEA in over a decade and the first regimen with median OS exceeding 2 years.
Post angle: Major regulatory milestone in HER2+ gastric/GEJ/esophageal cancer: zanidatamab ± tislelizumab now under FDA Priority Review (PDUFA Aug 25). HERIZON-GEA-01 hit mOS of 26.4 mo (zani+chemo+tisle) and 24.4 mo (zani+chemo) vs 19.2 mo with trastuzumab. The 1L HER2+ standard may finally change. #GastricCancer #GEA #HER2 #Zanidatamab #GIOnc
#3
Source: Nature Medicine | Authors: Trost F, Zhang B, Aring I, et al. | Published: April 29, 2026
Score: 10/20 — Base 9 (Nature Medicine) + 1 (biomarker / precision-pathology infrastructure)
SPARK (System of Pathology Agents for Research and Knowledge) is a foundational agentic-AI framework that uses natural language as the universal interface to autonomously generate biologically driven concepts for tumor analysis. Unlike conventional pathology AI, SPARK does not require additional model training and works directly on complex histopathology data. It was evaluated across 18 patient cohorts spanning five cancer types — including colorectal cancer — and more than 5,400 patients with histopathology and clinical follow-up. SPARK produced clinically and biologically relevant concepts correlated with prognosis, known pathology variables, and predictive biomarkers, and could infer patterns of tumor progression and temporal change from static images. All code, parameters, and results are openly released. The work points to a near-future where agentic AI augments — rather than replaces — pathologists in biomarker discovery and prognostication, including in CRC.
Post angle: Pathology meets agentic AI: SPARK autonomously generates and tests biological concepts on histopathology slides across 5 cancer types incl. CRC (5,400+ patients). It rediscovers known prognostic patterns AND finds new ones — with full open-source release. The next decade of digital pathology starts here. #DigitalPathology #AI #CRC #PrecisionMedicine #GIOnc
#4
Source: Gut | Authors: Mukherjee S, Antony A, Patnam NG, et al. (Mayo Clinic / MD Anderson / Univ. Washington) | Published: April 28, 2026
Score: 10/20 — Base 8 (Gut) + 2 (early-detection paradigm shift / SOC potential)
Failure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDAC) at the visually occult, pre-diagnostic stage is a primary reason for its dismal survival. REDMOD (Radiomics-based Early Detection MODel) was trained on 969 patients (156 pre-diagnostic, 813 controls) and tested independently in 493 patients (63 pre-diagnostic, 430 controls), simulating a low-prevalence (~1:6) early-detection setting. The fully automated framework couples AI-driven segmentation with a heterogeneous ensemble built on 40 radiomic features (90% multi-scale wavelet-filtered) from SMOTE-balanced data. On the independent test set, REDMOD identified occult PDAC with AUC 0.82 and 73.0% sensitivity at a median 475-day lead time — nearly twice the sensitivity of expert radiologists (38.9%; p<0.001), and almost three times higher (68.0% vs 23.0%) at >24-month lead time. It showed strong longitudinal stability (90–92% concordance) and generalizable specificity across two independent cohorts (n=539; n=80). REDMOD positions us to shift PDAC from late-stage symptomatic diagnosis to pre-clinical interception in high-risk surveillance.
Post angle: A potential game-changer for pancreatic cancer screening: REDMOD detects occult PDAC ~475 days before clinical diagnosis on routine CT — 73% sensitivity vs 38.9% for radiologists, AUC 0.82, validated across institutions. If prospectively confirmed, this could finally make pre-clinical interception in high-risk PDAC patients reality. #PancreaticCancer #EarlyDetection #AI #Radiomics #GIOnc
#5
Source: Nature Medicine | Authors: Nature Medicine Editorial / Research Highlight | Published: April 23, 2026
Score: 10/20 — Base 9 (Nature Medicine) + 1 (refines screening / surveillance paradigm)
This Nature Medicine piece consolidates emerging molecular and pathologic evidence indicating that intestinal metaplasia (specifically goblet-cell–containing Barrett's epithelium) is the obligate cellular precursor to esophageal adenocarcinoma (EAC). The data argue against “cardia-type” non-goblet columnar mucosa as an independent EAC precursor and reinforce that surveillance should be focused on patients with confirmed intestinal metaplasia. Practically, this recalibrates how we counsel patients with non-goblet columnar mucosa, refines biopsy and surveillance protocols, and supports the central role of goblet-cell histology in EAC risk-stratification. The implications cascade into endoscopic ablation criteria, screening cohorts, and future biomarker-guided early-detection programs in a tumor type whose incidence has tripled in recent decades.
Post angle: Big-picture clarification for esophageal adenocarcinoma surveillance: only intestinal metaplasia (goblet-cell+ Barrett's) is the obligate precursor. Non-goblet columnar mucosa should not drive surveillance. This sharpens screening, biopsy strategy, and ablation thresholds in a rising-incidence tumor. #EsophagealCancer #Barretts #GIOnc #CancerScreening
Additional Papers of Interest
-
PNAS — Testa E et al. — Fra-2 (AP-1 family transcription factor) emerges as a key adaptive-resistance node to KRAS G12D inhibition in PDAC; Fra-2 targeting could deepen and prolong KRASi responses
-
PNAS — Hu W et al. — CYP1B1 fine-tunes redox/mitochondrial integrity to generate pathogenic Th17 cells, promoting both colitis and colitis-associated CRC; targetable axis for IBD-CRC prevention
-
Science Advances — Mao C et al. — Two-stage GPC3-targeted peptidic MRI probe achieves in situ signal amplification for molecularly precise detection of micro-hepatocellular carcinoma, addressing a key surveillance gap
-
Science Advances — Banu K et al. — IRS4 emerges as a high-therapeutic-index target across pediatric and adult solid cancers (including GI subsets) via DNA rearrangements or epigenetic up-regulation that drive PI3K signaling
-
Gastroenterology — Mahapatra SJ et al. — Comprehensive review of CP pathophysiology and a roadmap toward disease-modifying, organ-preserving, patient-tailored therapies for the chronic-pancreatitis-to-PDAC continuum
Back to all digests